CDx & #039;s WATS3D Highly Effective in Real World Setting

CDx Diagnostics said results from a recent multicenter prospective trial show the use of its WATS3D test increases the detection of both Barrett’s esophagus and esophageal dysplasia by more than 80%. The results were published in the latest issue of United European Gastroenterology Journal and featured in the American Society for Gastrointestinal Endoscopy (ASGE’s) Scope Tech Talk Video Series. The trial was conducted at 25 community-based gastrointestinal (GI) centers across the U.S. In the study, 4,203 patients were tested for esophageal disease. The findings show that with the inclusion of WATS3D overall detection of Barrett’s increased by 83%, while the detection of dysplasia increased by 88%. The study concludes that the sampling error can be improved dramatically with use of WATS3D. Join us at the BIOMEDevice Boston Expo,  April 18–19, 2018. Use promo code "MDDI" for 20% off conference registration and free expo access.   “There are a lot of technologies that only work in academic centers,” Mark Rutenberg, founder and CEO of CDx Diagnostics, told MD+DI. “A lot of things work in academia ... but don't work in a critical practice. WATS3D has been now shown to work extremely well in the academic settings and in the community practices. What this study shows is WATS3D works in the real world.” The test received regulatory clearance in 2012 and was launched in 2014, Rutenberg said.  WATS3D works by collecting a more varied sample of tissue than individ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Design News Source Type: news